Adding a LABA or LAMA to Current ICS Therapy for Uncontrolled Asthma

Kyle Jordan Fletke, MD,

Nel Trasybule, MD,

University of Maryland School of Medicine, Baltimore, Maryland

American Family Physician. 2024;110(4):346-347.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

1.Oba Y, Anwer S, Patel T, et al. Addition of long-acting beta₂ agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023(8):CD013797.
2.Centers for Disease Control and Prevention. Asthma. Data, statistics, and surveillance. Most recent national asthma data. Accessed June 8, 2024. https://www.cdc.gov/asthma/most_recent_data.htm
3.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Accessed June 8, 2024. https://ginasthma.org/2023-gina-main-report

These are summaries of reviews from the Cochrane Library.

This series is coordinated by Corey D. Fogleman, MD, assistant medical editor.

A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.